Started: 6/2019
Study Name: A phase III, observer-blind, randomized, multi-country study to assess the reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavirus (HRV) vaccine as compared to the xxx the GSK’s HRV vaccine, when administered as a 2-dose vaccination in infants starting at age 6-12 weeks.
Indication: RSV
Principal Investigators: Sahra Niazi, Steve Russell, Pam Zegers